Description
Stamaril Yellow Fever Vaccine Single-dose Vial + Diluent - Box of 1
This is a restricted schedule drug. Only to be sold to medical professionals. You will be required to provide your APHRA Registration Number/Scheduled Drug License.
Live, attenuated yellow fever vaccine (17D strain) for active immunisation of adults and children ≥9 months who are travelling to, living in, or working in areas with yellow fever risk (or when a certificate is required). Supplied as 1 lyophilised single-dose vial + 0.5 mL diluent syringe for reconstitution. S4 (Prescription Only Medicine).
Key features
-
Who it’s for: People ≥9 months travelling to or living in at-risk areas; also for certain laboratory workers. Vaccination must be performed at an approved Yellow Fever Vaccination Centre and recorded on an International Certificate of Vaccination (ICVP). The ICVP becomes valid 10 days after primary vaccination and is valid for life.
-
Dose & route: Single 0.5 mL dose IM or SC. Do not give IV. In bleeding disorders/thrombocytopenia, use SC route.
-
Reconstitution & use: Reconstitute the powder with the supplied 0.4% sodium chloride diluent; shake well and use immediately (single-use only; discard residue).
-
Presentation: 1 × single-dose vial + 0.5 mL diluent syringe (latex-free stopper information is per PI/pack). Shelf-life 36 months at 2–8 °C.
-
Storage: Refrigerate 2–8 °C. Protect from light. Do not freeze. Maintain cold chain.
-
Supply note: In Australia, STAMARIL is supplied only to approved Yellow Fever Vaccination Centres.
Composition (per 0.5 mL after reconstitution)
Live attenuated 17D yellow fever virus, ≥1000 IU in stabiliser. Excipients include lactose monohydrate, sorbitol, histidine HCl, alanine, sodium chloride, potassium chloride, sodium phosphate (dibasic), potassium phosphate (monobasic), calcium chloride dihydrate, magnesium sulfate heptahydrate. Diluent: 0.4% sodium chloride.
Contraindications & precautions (selection)
Do not use in infants <6 months, people with severe egg/chicken protein allergy, thymus disorders, or immunodeficiency (incl. certain HIV or immunosuppressive therapy). Rare risks include YEL-AND and YEL-AVD; risk increases with age ≥60 years—weigh risks/benefits. See full PI for details.
Regulatory
ARTG ID: 58571
Sponsor: Sanofi-Aventis Australia Pty Ltd
PI last revised: 9 Nov 2023. PI/CMI available via TGA.
For healthcare professionals: Always consult the current Product Information and the Australian Immunisation Handbook for clinical use, co-administration and special-risk guidance.
